Assay

• US 20070031828A1
• Filed: 10/12/2006
• Published: 02/08/2007
• Est. Priority Date: 08/08/2001
• Status: Abandoned Application

• Current Assignee: DSM IP Assets BV (DSM-Firmenich AG), Japan Fine Coatings Co. Ltd. (JSR Corporation), JSR Japan Synthetic Rubber Company Limited
• Original Assignee: Glaxosmithkline Biologicals SA Delft Diagnostic Laboratory
• Inventors: Martin, Marie-Therese, Dubin, Gary, Quint, Wim, Colau, Brigitte Desiree, Van Doorn, Leen-Jan
• Application Number:
  US11/581,251
• Publication Number:
  US 20070031828A1
• Time in Patent Office: Days
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

A process for identification of type-specific polynucleotide sequences in a sample, the process comprising the steps of (1) contacting polynucleotides from the sample, or derived from the sample, with a plurality of type-specific probes in the context of a solid support, and detection of any type-specific hybridisation; and (2) contacting polynucleotides in the sample, or derived from the sample, with type-specific primers for those types capable of being detected by the hybridisation step in step 1, but not so detected, in a type-specific amplification reaction.

Claims

1. A process for identification of type-specific polynucleotide sequences in a sample, the process comprising the steps of:

(i) contacting polynucleotides from the sample, or derived from the sample, with a plurality of type-specific probes in the context of a solid support, and detection of any type-specific hybridisation; and

(ii) contacting polynucleotides in the sample, or derived from the sample, with type-specific primers for those types capable of being detected by the hybridisation step in step 1, but not so detected, in a type-specific amplification reaction.

2. A process according to claim 1 additionally comprising a first step of amplifying polynucleotides from the sample using broad spectrum primers and subsequent use of said amplified polynucleotides in step (i)

3. A process according to claim 2, wherein polynucleotide sequences amplified by broad spectrum primers are analysed to confirm the presence of general polynucleotide types of interest prior to hybridisation.

4. A process according to claim 1 wherein the type specific amplification is quantitative.

5. A process according to claim 1, wherein the type specific primers are specific for one of HPV 16, 18, 31, 33, 45, 52, 58, 35, 56, and 59

6. A method for identification of an individual at risk from disease, the method comprising detecting and typing of a polynucleotide correlated with the disease in a sample from the individual using the process according to claim 1.

7. A diagnostic kit for use in the process of claim 1 comprising at least one set of suitable broad spectrum primers in combination with at least one set of type-specific primers.

8. A kit according to claim 7 comprising HPV 16 and/or HPV 18 type-specific PCR primers.

9. A process, method or kit according to claim 1 for the typing of HPV, HIV-1, HCV, HBV, CMV, EBV, HDV, HGV, HSV, HHV, VZV, Helicobacter pylori, Mycobacteria, mycoplasma, rotavirus or gene p53.

10. A process, method or kit according to claim 9 for the typing of HPV.